component in Lewy bodies), via the vagal nerve. This hypothesis, however, has not been tested experimentally thus far. Here, we use a human PD brain lysate containing different forms of α-synuclein (monomeric, oligomeric and fibrillar), and recombinant α-synuclein in an in vivo animal model to test this hypothesis. We demonstrate that α-synuclein present in the human PD brain lysate and distinct recombinant α-synuclein forms are transported via the vagal nerve and reach the dorsal motor nucleus of the vagus in the brainstem in a time-dependent manner after injection into the intestinal wall. Using live cell imaging in a differentiated neuroblastoma cell line, we determine that both slow and fast components of axonal transport are involved in the transport of aggregated α-synuclein.
also widely exhibited in non-dopaminergic systems. The progressive spread of the Lewy pathology, which is characterized by α-synuclein immunoreactive inclusions in cell bodies and neuronal processes, marks the core of neuropathological staging in most cases of PD. The topographic distribution of such α-synuclein-containing inclusions, first appear in the peripheral nervous system (e.g., enteric neurons in the gut), progresses to lower brain regions, such as the dorsal motor nucleus of the vagus (DMV) and to the substantia nigra (where the primary lesion of dopaminergic neurons locates in PD). Eventually inclusions can be detected in the cerebral cortex. These findings give rise to the notion that a neurotropic pathogen would penetrate the gut epithelium and enter axons of the enteric neurons in the myenteric plexus (Auerbach's plexus); these neurons control the activity of gut smooth muscles; and/or axons of the submucosal plexus (Meissner's plexus), which regulates mucosal secretion and blood flow.
Braak and co-workers hypothesized that this pathogen might spread via retrograde transport to different interconnected brain regions [5, 6, 17] . In Braak's observations, Lewy pathology first manifests in enteric neurons of the gut (stage 1) long before it is present in dopaminergic neurons of the midbrain and PD symptoms are evident (stage 3) [7] . The gap between stages 1 and 3 may take many years. From the periphery, the pathology gains access to the lower brainstem via the vagal nerve and then follows an ascending pathway reaching the substantia nigra and subsequently, the cerebral cortex [28, 40] . Thus, the temporal appearance of Lewy pathology in PD strongly suggests long-distance trafficking of a pathogen in neurons from peripheral tissues to the brain.
We, and others, have shown that intra-striatal transplants of fetal ventral mesencephalic progenitors in PD patients develop Lewy pathology a decade after transplantation, suggesting transfer of Lewy pathology from host to the grafted cells [21-23, 29, 30] . Further experimental studies have shown that Lewy pathology can indeed propagate from one cell to another, not only in cultured cells in vitro, but also in brains of animal models of PD [11, 15, 27, 33] . Moreover, recent reports revealed that α-synuclein could spread along the projection tracts after it was directly injected into the brain of α-synuclein transgenic or wildtype mice [31, 32, 43] and Lee et al. [26] elegantly showed deposition of α-synuclein in myenteric neurons after injecting the brain lysate derived from the patient of dementia with Lewy body (DLB), into the stomach wall of A53T transgenic mice. But, to date, experimental evidence is lacking to show whether α-synuclein pathology can propagate from the gut to the brain, as hypothesized by Braak and his colleagues.
Here, we show that α-synuclein from PD patient brain lysate is taken up and transported retrogradely over a long distance via the vagal nerves from the gut to the brain, after being injected into the wall of the gastrointestinal tract. We confirmed these observations using Atto-550-labeled recombinant α-synuclein forms (monomers, oligomers and fibrils). Additionally, we provide evidence suggesting that aggregated α-synuclein is transported by the fast component of microtubule-based axonal transport as well as in the slow component of axonal transport. Taken together, our findings strengthen the hypothesis that PD pathology may originate in the periphery and gradually propagate to the brain, where it eventually leads to PD.
Materials and methods

Animals
Adult wildtype Sprague Dawley rats (approximately 250 g) were purchased from Charles River Laboratories. Animals were kept with food and water ad libitum under a 12-h light/12-h dark cycle. Housing and procedures were conducted in accordance with ethical permit approved by Malmö-Lund Committee for animal research.
Preparation of brain lysates from PD patient
Brain of a neuropathologically confirmed PD case was provided by Dr. Elisabet Englund, the Brain Bank, Lund University Hospital, Sweden. The patient died of acute aspiration and subsequent cardiac arrest due to advanced PD. Fresh substantia nigra was dissected out (20 h postmortem), immediately frozen and stored in −80 °C freezer until use. Lysates containing aggregated as well as mono-and oligomeric forms of α-synuclein were prepared with the freshly frozen substantia nigra tissue. The tissue was homogenized at 10 % (w/v) in sterile, phosphate-buffered saline (PBS) at 4 °C, vortexed, sonicated 3 × 5 s and centrifuged at 3,000×g at 4 °C for 5 min. Supernatants were kept frozen at −80 °C. The solution for injection was prepared by diluting the PD patient's lysate supernatant before use to a final concentration of 3 % (w/v). Different forms of α-synuclein (1 µg/µl) were resuspended in PBS with or without fluorogold (40 µg/ml).
Preparation of recombinant α-synuclein in monomeric, oligomeric, and fibrillar forms
Expression and purification of recombinant α-synuclein
The expression and purification of human wildtype (WT) α-synuclein was performed as previously described [14] . Briefly, the Escherichia coli strain BL21 (DE3) (Stratagene, La Jolla, CA, USA) were transformed with the expression vector pET3a encoding WT α-synuclein and the bacteria grown in LB medium to an optical density of 0.8. α-Synuclein expression was induced by 0.5 mM IPTG for 3 h, the cells were lyzed by sonication and the cell lysates were clarified by centrifugation at 14,000g, for 30 min. α-Synuclein was precipitated by 50 % ammonium sulfate at 4 °C. The solution was spun at 4,000 g, for 30 min at 4 °C and the resulting pellet was resuspended in 10 mM Tris pH 7.5. The solution was loaded onto a DEAE column eluted by a gradient of 0-500 mM NaCl, and the fractions containing α-synuclein (eluted at 200 mM NaCl) were heated to 75 °C for 20 min. The solution was next clarified by centrifugation at 14,000g, loaded onto a Superdex 75 HiLoad 26/60 column (GE healthcare), equilibrated and eluted in 50 mM Tris-HCl, pH 7.5, 150 mM KCl. Pure α-synuclein (0.2-0.5 mM) in 50 mM Tris-HCl, pH 7.5, 150 mM KCl was filtered through sterile 0.22-µm filters and stored at −80 °C. α-Synuclein concentration was determined spectrophotometrically using an extinction coefficient of 5,960 M −1 cm −1 at 280 nm.
Assembly of monomeric α-synuclein into oligomers and fibrils
For oligomer formation, α-synuclein (200 µM) was incubated in buffer A (50 mM Tris-HCl, pH 7.5, 150 mM KCl) at 4 °C, without shaking, for 7 days. Oligomeric α-synuclein was separated from the monomeric form of the protein by size-exclusion chromatography (Superose 6 HR10/300, GE Healthcare). For fibril formation, α-synuclein was incubated in buffer A at 37 °C under continuous shaking in an Eppendorf Thermomixer set at 600 r.p.m. Assembly was monitored continuously in a Cary Eclipse spectrofluorimeter (Varian Inc., Palo Alto, CA, USA) in the presence of Thioflavin T with excitation wavelength set at 440 and emission wavelengths set at 480 and an averaging time of 1 s.
Fluorescent labeling of monomeric, oligomeric and fibrillar α-synuclein assemblies and BSA
Monomeric and oligomeric α-synuclein assemblies in buffer A were buffer exchanged using NAP10 desalting columns (GE Healthcare) to phosphate-buffered saline (PBS) buffer. We performed α-synuclein labeling with Atto-550 NHS ester fluorophore following the manufacturer's instructions (Atto-Tec Gmbh) using a protein:label molar ratio of 1:2 as such two Atto molecules per alpha-synuclein monomer whether monomeric, oligomeric or fibrillar form. The labeling reactions were arrested by addition of 1 mM Tris pH 7.5. We removed unreacted fluorophore using NAP10 desalting columns.
For fibrillar α-synuclein labeling, the fibrils were centrifuged twice at 15,000g for 10 min, resuspended twice in PBS and labeled as described above. The unreacted fluorophore was removed by a final cycle of two centrifugations at 15,000g for 10 min and resuspension of the pelleted fibrils in PBS. Lyophilized BSA was purchased form Sigma (A9418), dissolved in PBS at 5 mg/ml and labeled with ATTO-550 dye using a protein:dye ratio of 1:2 following the same procedure as described for monomeric α-synuclein.
Electron microscopy imaging
The nature of soluble, oligomeric and fibrillar α-synuclein forms was assessed using a JEOL 1400 transmission electron microscope following adsorption onto carbon-coated 200-mesh grids and negative staining with 1 % uranyl acetate. The images were recorded with a Gatan Orius CCD camera (Gatan).
Operation procedures
Animals were anesthetized using isoflurane (2-4 %) and kept at a constant body temperature by the use of a conventional heat pad. A schematic showing how the in vivo experiments were performed is depicted in Fig. 1 . For each animal, injections were made using a 10-µl Hamilton syringe into the intestine wall of stomach and duodenum at 5 sites, 1 cm apart. Injections were made in close proximity to the myenteric plexus. Each site was injected with 3 µl of one of the four different forms of α-synuclein (PD brain lysate (2 µg/µl, in total protein content), monomer (1 µg/µl), oligomer (1 µg/µl) or fibril (1 µg/µl), n = 3 in each type and each time point). In addition, control animals (n = 3) were injected with BSA diluted (1 µg/µl) in phosphate-buffered saline (PBS). Some of the animals were injected with a mixture of the synuclein forms and fluorogold. Following injection, animals were sutured and returned to normal housing conditions.
Tissue collection
After 12 (n = 15), 24 h (n = 15), 72 h (n = 15) and 6 days (n = 12) injected animals were anesthetized with sodium pentobarbital and then transcardially perfused with 0.9 % saline followed by fixation using ice-cold 4 % paraformaldehyde (PFA) in PBS. A length of the vagal nerve, ranging from the brainstem to the diaphragm (~80 mm) as well as the brain and segments of the intestine were dissected and post-fixed in 4 % PFA overnight. Tissues were then stored in 0. Sections were then incubated with a biotinylated antimouse secondary antibody (Vector 1:400) at room temperature for 2 h followed by incubation with ABC kit (Vectastain) and DAB kit (Vector laboratories) conventional peroxidase system. Brightfield images were captured on a BX53 Olympus microscope.
Immunofluorescent labeling
We stained transverse sections of medulla oblongata as free-floating on a shaker, while vagal nerve sections were stained mounted on glass slides using a primary antibody specific for human α-synuclein to detect transported α-synuclein. Sections were incubated with the following antibodies: anti-α-synuclein (mouse monoclonal, Santa Cruz 211 1:1,000), anti-choline acetyltransferase (goat, Millipore AB144P 1:500) in combination with secondary antibodies; Alexa-555 anti-mouse (Jackson 1:800), Alexa-488 anti-goat (Jackson 1:800), FITC anti-rabbit (Jackson 1:200). Confocal microscopic images of doublelabeled medulla oblongata were captured using a Leica SP8 Scanning confocal microscope using a HyD detector using sequential scanning. Solid-state lasers at wavelengths 488 nm and 552 nm were utilized to excite the respective fluorophores. The pinhole was retained at Airy 1 for all acquisitions. For each acquisition at the same magnification, identical settings were loaded for laser power gain. Post-acquisition, deconvolution was performed using the "Deconvolution" plugin for ImageJ [developed by the Biomedical Imaging Group (BIG), EPFL, Switzerland http://bigwww.epfl.ch/] utilizing the Richardson-Lucy algorithm and applying point-spread functions (PSFs) calculated for the specific imaging equipment using the Gibson and Lanni model in the PSF Generator (BIG, EPFL, Switzerland http://bigwww.epfl.ch/algorithms/psfgenerator/). The same PSF models and deconvolution parameters were applied to all image stacks at the same magnification. Orthogonal projections were generated using ImageJ (v1.48p) without further modifications of the images.
Western blotting
Tissue protein extraction
The substantia nigra of a Parkinson patient (advanced stage) was obtained from Lund Brain Bank, kindly supplied by Dr. Elisabet Englund. The sample was homogenized in the presence of proteases inhibitors using a FastPrep-24 homogenizer (MP Biomedicals, Santa Ana, CA, USA) in a lysis buffer 50 mM Tris/HCl pH 7.4, 150 mM NaCl, 2 mM EDTA, 1 % (v/v) NP-40, 0.1 % (w/v) sodium dodecyl sulfate for further analysis by SDS-PAGE or in lysis buffer 20 mM Tris/HCl pH 7.4, 100 mM NaCl, 0.4 % (w/v) sodium dodecyl sulfate and 0.2 % (v/v) Triton X-100 for Native PAGE. Tissue homogenate was further sonicated twice for 10 s at 30 % amplitude (QSonica, Newtown, CT, USA) with 1-min incubation on ice between each sonication step and centrifuged at 16,000g for 15 min at 4 °C. The supernatant was recovered and protein concentration was quantified using BCA protein assay (Thermo Fisher Scientific, Rockford, IL, USA).
SDS-PAGE, native PAGE and Western blotting analysis
Brain extract from a patient developing PD, monomeric, oligomeric and fibrillar α-syn were either mixed with SDS-PAGE loading buffer and heated to 100 °C and analyzed on a 8-16 % polyacrylamide gel or with Native PAGE loading buffer and analyzed on a 8-16 % polyacrylamide. The samples were transferred to nitrocellulose membranes and probed with mouse anti-α-synuclein-1 antibody (S63320 BD Transduction Laboratories 1:1,000 dilution).
Cell culture, transfection and differentiation
Stable human neuroblastoma SH-SY5Y cells (passage 7-10) were maintained in DMEM Glutamax media (Gibco) supplemented with 10 % FBS (Sigma) in a humidified 5 % CO 2 atmosphere at 37 °C. On the first day of the experiment, 20,000 cells were seeded into the center wells of four-well borosilicate glass chamber slides (Nunc) coated with matrigel (BD Bioscience), the Fig. 1 Characterization of α-synuclein forms from PD brain lysate and recombinant proteins injected into the intestinal wall. a A section of the substantia nigra of the PD patient that the brain lysate for injection was generated from was subjected to immunohistochemistry with an antibody raised specifically against human α-synuclein.
The low-power image shows an overview of Lewy pathology (scale bar 30 μm). The high-power image (inset) shows detail of distinct Lewy body (scale bar 10 µm). [3, 48] . Before each imaging session media were replaced with imaging buffer consisting of HBSS (Life technologies) supplemented with 5 mM glucose, 1.8 mM CaCl 2 , 1 mM MgCl 2 and 20 mM HEPES, pH 7.4. Working at 256 × 256 pixel resolution, pre-and post-bleaching images were collected using 0.8 % laser power to avoid photobleaching and phototoxicity at a rate of 5 Hz with pinhole set to maximum. Each experiment started with the collection of 4 baseline images. Bleaching was then performed with 100 % laser power for 5 iterations within a circular field 100 µm in diameter, covering an area of the neurite located 100-200 μm away from the cell body. Following the photobleach, fluorescence intensities were recorded for 44 s in bleached, cell body reference and background regions. For each group; expressing α-synuclein-BiFC-Venus (n = 4), α-synuclein-Venus (n = 5), Actin-GFP (n = 6) and Venus alone (n = 5) three cells were imaged. Values averaged from the three cells in each experiment constitute one n. To investigate whether mobility was dependent on microtubule dynamics, separate experiments were then performed in which 10 nM of vinblastine was added to the media, after 1-h incubation groups α-synuclein-BiFC-Venus (n = 2), α-synucleinVenus (n = 3), Actin-GFP (n = 5) and Venus alone (n = 5) were imaged. 
Statistical analysis
All data were analyzed using GraphPad Prism software (developed by GraphPad Software, San Diego, USA http:// www.graphpad.com). FRAP groups were analyzed by oneway ANOVA for difference among the groups, then groups in-between were compared pairwise by student's t test.
(1)
Figures and artwork Vector graphics and schematics were created using Adobe illustrator CS5 and figures arranged and compiled using Adobe InDesign CS5.
Results
α-Synuclein from a PD patient lysate is transported via the vagal nerve from the intestine to the brain α-Synuclein is an abundant protein in the neuron. In the brain of PD patients, the protein is misfolded and aggregated, forming Lewy bodies and Lewy neurites in dopaminergic neurons of the substantia nigra as well as in other types of neurons in different brain regions. We first collected fresh substantia nigra tissue from a neuropathologically confirmed Parkinsonian case. Immunohistochemical analysis confirmed the presence of distinct α-synuclein-positive Lewy body structures in brain sections (Fig. 1a) . This tissue was therefore used for PD brain lysate preparation. Here, we performed biochemical analyses of the brain lysate preparation to assess the different forms of α-synuclein it contained. Under denaturing conditions, in the presence of SDS, α-synuclein appears monomeric with a molecular weight of ~17 kDa (Fig. 1b) ; while the native PAGE reveals the presence of higher molecular α-synuclein forms in the brain lysate (Fig. 1b) .
After confirming the presence of the α-synuclein forms in the lysate, we injected 3 µl of this lysate (2 µg/µl, total protein) into the intestine of wildtype adult rats (Fig. 1c) and assessed the presence of α-synuclein in the vagal nerve by immunohistochemistry using an antibody that specifically recognize human α-synuclein (See: Materials and methods). We detected distinct α-synuclein immunoreactivity in the intestinal wall (Fig. 1d, middle panel) and in the vagal nerve at time-dependent matter (12, 48 , and 72 h post-injections) (Figs. 2, 3 , middle panels). No human α-synuclein was detected in the controls, which were injected with bovine serum albumin (BSA) (Figs. 1d, 2) . When a BSA antibody was used, no distinct immunoreactivity was detected in the vagal nerves at different time points (Supplement Fig. 1) .
Together, these experiments demonstrate that the PD brain lysate contains different α-synuclein forms, and they show that α-synuclein from the injected lysate is taken up and transported via the vagal nerve to the brain. In contrast, although BSA is present in the injection site of the intestinal wall, it is not taken up and transported into the vagal nerve.
Different α-synuclein forms are transported from the intestine to the brain via the vagal nerve
We have shown that the brain lysate contains a mixture of monomeric and multimeric α-synuclein forms. However, it is not clear which form(s) of the protein is taken up and transported to the vagal nerve. Thus, we performed the experiments with distinct, characterized α-synuclein forms. These were fluorescently labeled to allow direct visualization; we determined the nature of each α-synuclein form by SDS-PAGE and native PAGE (Fig. 1b) and transmission electron microscopy (Fig. 4a) . Size-exclusion chromatography analyses further revealed the defined and size-specific forms of α-synuclein used in the experiments (Fig. 4b) .
When aggregated α-synuclein in the form of fibrils was injected, we observed distinct α-synuclein in the intestinal wall (Fig. 1d) and in the vagal nerve at time-dependent manner ( Fig. 2) , similar to the PD brain lysate. Particularly, in the high-power images, we could clearly see intensely immune-stained nerve fibers of the vagal nerves in the PD brain lysate-and fibril-injected animals (Fig. 3) . In order to verify that different forms of α-synuclein are indeed transported from the intestines to the brain, we injected monomeric, oligomeric or fibrillar Atto-550-α-synuclein with fluorogold, (a live dye, used as a control for the injection) into the intestinal wall of the adult rats. Forty-eight hours later, we detected fluorogold and Atto-550 positive fluorescent punctae in neurons in the DMV, for monomeric, oligomeric and fibrillar forms of α-synuclein we injected. Most, if not all, Atto-550-α-synuclein-positive structures overlapped with fluorogold fluorescence (Supplement Fig. 2a-c) . When fluorogold was co-injected with unlabeled PD brain lysate, no Atto-550 fluorescence was observed (Supplement Fig. 2d ). These data strongly indicate that the human α-synuclein found in the neurons of the DMV was transported from the injected sites within the intestine.
The neurons of the DMV are cholinergic. To further verify that the human α-synuclein in the DMV is transported from the gastrointestinal wall via the vagal nerve, we double-stained brain sections of medulla oblongata with antibodies against the phenotypic cholinergic enzyme, choline acetyltransferase (ChAT) and human α-synuclein. In samples collected 6 days after intestinal injection, nearly all neurons positively stained for human α-synuclein were also positive for ChAT (Fig. 5b-e) . In contrast, no α-synuclein immunoreactivity was detected in controls (BSA-injected animals; Fig. 5a ). Interestingly, the animals sacrificed 24 h post-injection did not show any human α-synuclein immunoreactivity in ChAT-positive neurons in the DMV region (Supplement Fig. 3 ). These data further suggest that different α-synuclein forms are transported over a long distance from the intestine to the brain in a time-dependent manner. Transport pattern of aggregating α-synuclein α-Synuclein is a soluble, unfolded protein, which forms α-helical structures when membrane bound. Previously, we demonstrated that the majority of soluble α-synuclein is located within the cytosol and transports via slow axonal transport, including slow component a (SCa) and slow component b (SCb), while a small fraction (about one quarter) of the total cellular α-synuclein is membrane associated and transports through fast axonal transport, i.e., the fast component [19] . Membrane-bound α-synuclein is α-helical and does not contribute to aggregation and fibrillation, while the soluble form of the protein populates folding intermediates that oligomerize and assemble into fibrils. Our in vivo experiments show that monomeric, oligomeric and fibrillar forms of α-synuclein a b Fig. 4 Characterization of α-synuclein forms. a Negatively stained transmission electron micrographs of monomeric, oligomeric and fibrillar α-synuclein. (Scale bar represents 200 nm) . b Size-exclusion chromatography analysis of monomeric and oligomeric α-synuclein. Elution profile of pure recombinant monomeric (top) oligomerized α-synuclein (middle) and oligomeric α-synuclein incubated 7 days at 4 °C, from a Superose 6 (HR 10/30) column (bottom). Arrows show the location of oligomeric and monomeric α-synuclein. Solid arrowheads show the location of molecular size markers (thyroglobulin 670 kDa; immunoglobulin G 158 kDa; ovalbumin 44 kDa and myoglobin 17 kDa) run under identical conditions on the same column Fig. 5 Atto-550-α-synuclein forms specifically transported into the DMV, 144 h after injection into the wall of the intestine. To enhance the signal the brain sections were immunostained with antibodies directed specifically against human α-synuclein (Syn211, red, a-e, a″-″, a″′-e″′) and ChAT (green, da-e, a′-d′, a″′-e″′), the phenotypic markers of the DMV. Monomeric (b), oligomeric (c), fibrillar (d) α-synuclein and PD patient brain lysate (e) injected animals display double-labeled neurons (arrows), while BSA injection does not yield any α-synuclein-positive neurons (a″). Scale bars 25 µm in a-e, and 10 µm in a″′-e″′ are retrogradely transported from the intestine to the brain via the vagal nerve. However, it is not clear which machinery is involved in the transport of different α-synuclein forms, especially the aggregated ones (oligomers and fibrils), which likely contribute to pathology of PD [10, 34, 50] . As live-cell imaging would be technically challenging to perform in living animals, we used an in vitro system where cultured differentiated neuroblastoma cells (from the SH-SY5Y line), which exhibit neuronal morphology, were transfected with α-synuclein constructs expressing human α-synuclein tagged with full-length fluorescent protein (Venus) or co-transfected with Bimolecular Fluorescence Complementation (BiFC) truncated parts of a Venus, which upon dimerization and oligomerization of α-synuclein reveals fluorescence [15, 35] . Taking advantage of this system that allows us to visualize both total α-synuclein and specifically the aggregated α-synuclein with complemented fluorescence, we performed fluorescence recovery after photobleaching (FRAP) experiments in differentiated SH-SY5Y cells (Fig. 6a, b; Supplement Fig. 4) . Functionality of axons in differentiated cells was validated by transfection using a mito-GFP construct visualizing active transport of mitochondria by live cell imaging (Supplement Movie).
To study the motility of aggregating α-synuclein, we first asked whether the transport of aggregated α-synuclein in neurons occurs by an active process (protein-protein interaction) or by passive diffusion. We use two distinct models that represent these forms of transport, respectively. Cells, expressing full-length Venus alone (empty vector) or actin-GFP were used as controls. Venus alone, being a freely diffusing protein independent of molecular interactions, displayed a complete recovery of signal following photobleaching returning to the pre-bleach level (p < 0.0001) as expected. In contrast, we observed α-synuclein-Venus and the complemented α-synucleinBiFC-Venus signal to recover only to 75 % of the prebleach intensity (p < 0.0017). Actin-GFP showed a much lower recovery (p < 0.0002), typical of a low motility protein dependent on protein-protein interaction. This was also expected, as actin has been documented to be primarily transported in SCb [4] . The rapid, but partial, recovery of complemented α-synuclein-BiFC-Venus suggests that it is involved in protein-protein interaction (Fig. 6b, c) . As expected, similar results were seen for total α-synuclein-Venus. Fast axonal transport is microtubule based, and microtubule itself is transported in SCa. To investigate whether transport of aggregated α-synuclein was microtubule dependent, we treated the cultures with 10 nM vinblastine, an agent known to destabilize microtubules [2, 20] , for 1 h before the FRAP experiment. The treatment affected neither the protein mobility of actin-GFP nor that of Venus alone (p = 0.1586 and p = 0.1618, respectively). No increase in mobility was observed for α-synuclein-Venus reflecting the whole pool of protein regardless of being interacted to subcellular components or not (e.g., membrane bound, microtubule or soluble). The BiFC approach offers the unique opportunity to exclusively visualize the aggregating (oligomeric) form of α-synuclein. In this group, we observed a significant increase in mobility following treatment (Fig. 6d, p = 0.00948) . The level of mobility of aggregated α-synuclein in vinblastine-treated cells was comparable to that of free diffusion, as seen in cells expressing Venus alone (Fig. 6d, p = 0.64074 ). This 25 % increase, for oligomeric α-synuclein, following vinblastine treatment shows that aggregated α-synuclein is directly interacting with microtubule in functional axons of neuron-like cells, suggesting aggregated α-synuclein is likely transported both by the fast component (microtubule based) as well as SCa and SCb.
Discussion
In the present study, we demonstrate that aggregated α-synuclein is transported from the intestine to the brain. Our in vitro data also suggest that aggregated α-synuclein is transported through both fast and slow axonal transports.
α-Synuclein and its aggregated forms are transported in long distance from the intestine to the brain After intensive studies, Braak et al. [6] [7] [8] proposed the six stages of neuropathology during PD pathogenesis. The first sign of Lewy pathology appears in the projection neurons of the dorsal motor nucleus of the vagus at the early stage of PD [9] . Later on, the vulnerable brain regions are affected in a predictable sequence, progressing in a stereotypical caudal-rostral pattern starting in the lower brainstem, medulla oblongata, and exhibiting the pathology in more rostral regions later. A key question is how this stepwise temporal appearance is developed over time (over many years in humans). Braak hypothesized that the Lewy pathology retrogradely progresses from the intestine to the brain. However, some studies have argued against the findings of the Braak hypothesis, by showing non-stereotypic patterns of Lewy pathology [18, 37, 38] . In the present study, we provide direct evidence that retrogradely transported α-synuclein forms indeed lead to spread of the Lewy pathology from the peripheral tissue (gastrointestinal) to the brain via the vagal nerve. Similar phenomena are observed not only for monomeric α-synuclein, but also for oligomeric and fibrillar α-synuclein, the latter most likely being a significant contributor to the Lewy pathology propagation in PD conditions. The vagal route of α-synuclein transport has also been documented by systemic administration of the environmental toxin rotenone [36] , as well as by directly injecting adeno-associated viral vectors overexpressing human α-synuclein into the vagal nerve [49] . The clear difference between the present study and previous work is that exogenous α-synuclein forms are not readily detected in the vagal nerves/neurons and the brain parenchyma [15, 31, 32, 49] .
After being delivered to the gastrointestinal wall, α-synuclein must first be taken up into the vagal nerve terminals or indirectly to the enteric neurons and/or their terminals first, then trans-synaptically transfer via the synapses between the enteric neurons and the vagal nerves to reach the brain. Thus, the amount of transported α-synuclein is expected to be low. We found that all α-synuclein forms (monomers, oligomers and fibrils) are actively transported from the intestine to the dorsal motor nucleus of the vagus. It is, therefore, conceivable that the gut-to-brain route is an important route for α-synuclein propagation. The protein is taken up into the peripheral tissues and is transported to the lower brain. The spread of pathology is time dependent. Figure 6 illustrates the overview pattern of α-synuclein transport between the intestine and the brain. We readily observed distinct α-synuclein in the intestinal wall shortly (12 h) after injection, however, at the same time, we barely detected any α-synuclein in the vagal nerve, which became evident in the later time points. Correspondently, we did not detect any human α-synuclein in the DMV 24 h after the injection while considerable numbers of α-synucleinpositive neurons were observed in the later time points (72-144 h) after the injection. Although, we did notice a stronger α-synuclein-positive signal in the DMV of animals injected with monomeric and oligomeric α-synuclein compared to those injected with fibrillar form or PD brain lysate, suggesting a difference in propensity to transport, we hesitate for such conclusions since transport most likely also depend on the success and favorable quality of injection sites in each animal. Several groups elegantly showed that α-synuclein pathology spread along the neuronal connections after injecting the PD brain lysate, transgenic mouse brain lysate or preformed α-synuclein fibrils in the striatum and the cortex of mice or monkeys [31, 32, 42, 43] , where the exogenous α-synuclein induced a seeding effect of endogenous α-synuclein, suggesting a permissive templating prion-like process [16] . The time-dependent and connectivity-dependent spread of the Lewy pathology is closely accompanied by dopaminergic neuronal cell death at 90 and 180 days post-injection [31] . It is worth mentioning that we also examined potential cell death in the DMV with cell death markers, such as activated caspase 3, and α-synuclein presence in higher brain regions, such as the locus coeruleus and the substantia nigra (Fig. 7) . We neither detect distinct dying cells, nor exogenous α-synuclein in these brain regions (data not shown). The discrepancy between our findings and theirs could be due to the dose of delivered α-synuclein and incubation time (6 days vs. 90-180 days) following injection.
The mechanisms of transport of α-synuclein species Sufficient axonal transport is essential for neuronal function. Based on the speed of the trafficking, axonal transport is categorized into fast axonal transport (largely involved in membrane-bound organelles) with rates of 50-400 mm/day and slow axonal transports (SCa and SCb). SCa transports microtubules and neurofilaments at average rate of about 1 mm/day, while SCb transports handful soluble cytosolic proteins, including actin at average rate of about 2-8 mm/ day [47] . Roy and his co-workers reported that α-synuclein was transported in SCb. It appeared that α-synuclein cotransported with other SCb proteins [44] [45] [46] . Using stopflow/nerve crush operations and metabolic labeling of retinal ganglion cells, we demonstrated that (monomeric) α-synuclein is transported by all axonal transport components (fast transport, SCa and SCb) and that the majority of protein is transported through SCa and SCb, while one quarter is transported through fast axonal transport [19] . The oligomeric form of α-synuclein impairs microtubule-kinesin interaction and lead to early neurite pathology [41] and oligomeric and/or fibrillar α-synuclein is the vector of pathology propagation [1, 31, 42] . It is thus essential to understand the transport mechanism of oligomeric and fibrillar α-synuclein in neurons. In vitro studies with microfluidic chambers showed that preformed α-synuclein fibrils were not only taken up and transported within primary neurons but also transmitted to secondary neurons [13, 33] . Taking advantage of the unique strategy of BiFC, with the FRAP technique, we demonstrated that oligomeric α-synuclein and likely the fibrillar form as well, is directly associated with microtubule plausibly engaged in active transport. Likely, the aggregated forms of α-synuclein are involved in all form of axonal transports, as for monomeric α-synuclein by associating with fast transporting cargoes, interacting with microtubules and staying in soluble states. At certain conditions, such as phosphorylation or truncations, they may translocate from one subcellular compartment to another. Furthermore, we also demonstrated that assembled α-synuclein is retrogradely transported along long-distance ranges from the intestine to the brain. Given the fact that the full vagal nerve length is about 110-140 mm in adult rats from the DMV to the muscles in the intestine wall, our in vivo findings suggest an average translocation rate of 20-30 mm/day, i.e., faster Fig. 7 An overview of uptake and transport of BSA and α-synuclein in the PD brain lysate or synthetic recombinant α-synuclein fibrils, in the intestines, along the vagal nerve and in the medulla oblongata, at different time points than SCb in the reported range of fast microtubule-associated transport [24] , in support of multi-phasic transport. The actual transport rate is most likely faster as the estimated rate also covers the time required for accumulation of α-synuclein in the cell body in the DMV as well as time required for α-synuclein direct or indirect uptake into the axon of the projecting nerve cell. Because of the limitations of FRAP, specific membranous cargoes or transport motors that are involved in the transport of α-synuclein are yet to be evaluated.
The long-range anterograde and retrograde transport of α-synuclein assemblies may contribute to a complex spread of Lewy pathology. Numerous experimental evidences, including our present findings, support Braak's hypothesis that α-synuclein is transported retrogradely. Nonetheless, discrepant findings [18, 38] indicate diverse clinical features for PD with different subtypes of neuropathology.
In an independent study, we recently demonstrated that aggregated α-synuclein is also transported anterogradely in neurons, for example, from the cortex to the spinal cord (Unpublished observations). The bidirectional transport of α-synuclein assemblies may account for the complexity of PD pathology.
